Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies

详细信息    查看全文

• 作者：Kai Kaarniranta ; Kirsi Ikäheimo ; Eliisa Mannermaa ; Auli Ropo
• 刊名：Clinical Pharmacokinetics
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：55
• 期：4
• 页码：485-494
• 全文大小：586 KB
• 参考文献：1.The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.CrossRef
  2.Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRef PubMed
  3.Leske MC, Heijl A, Hussein M, Bengtsson B, Hyma L, Komaroff E, The Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.CrossRef PubMed
  4.Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53:S3–10.CrossRef PubMed
  5.European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: PubliComm; 2014. p. 141–2.
  6.Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patents with glaucoma or ocular hypertension an evidence based review. Ophthalmology. 2005;112:953–61.CrossRef PubMed
  7.Denis P. Adverse effects, adherence and cost-benefits in glaucoma treatment. Eur Ophthalmic Rev. 2011;5:116–22.CrossRef
  8.Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.PubMed PubMedCentral
  9.Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360–8.CrossRef PubMed
  10.Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–6.CrossRef PubMed
  11.Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–26.CrossRef PubMed
  12.Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02 % benzalkonium chloride. Br J Ophthalmol. 2008;92:1275–82.CrossRef PubMed PubMedCentral
  13.Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.CrossRef PubMed
  14.Tressler CS, Beatty R, Lemp MA. Preservative use in topical glaucoma medications. Ocul Surf. 2011;9:140–58.CrossRef PubMed
  15.Pellinen P, Huhtala A, Tolonen A, Lokkila J, Mäenpää J, Uusitalo H. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res. 2012;37:145–54.CrossRef PubMed
  16.Stalmans I, Sunaric MG, Cordeiro MF, Hommer A, Rossetti L, Goñi F, Heijl A, Bron A. Preservative-free treatment in glaucoma: who, when, and why. Eur J Ophthalmol. 2013;23:518–25.CrossRef PubMed
  17.Brandt JD. Does benzalkonium chloride cause cataract? Arch Ophthalmol. 2003;121:892–3.CrossRef PubMed
  18.Rossi GC, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23:296–302.CrossRef PubMed
  19.Boimer R, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–5.CrossRef PubMed
  20.Mastropasqua L, Agnifili L, Mastropasqua R, Fasanella V. Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr Opin Pharmacol. 2013;13:56–64.CrossRef PubMed
  21.Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.CrossRef PubMed PubMedCentral
  22.Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.PubMed
  23.Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.CrossRef PubMed
  24.Crichton AC, Vold S, Williams JM, Hollander DA. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013;30:260–70.CrossRef PubMed
  25.Mathews PM, Ramulu PY, Friedman DS, Utine CA, Akpek EK. Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology. 2013;120:2241–8.CrossRef PubMed
  26.Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–9.CrossRef PubMed
  27.Niwano Y, Iwasawa A, Ayaki M. Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog. Ophthalmol Eye Dis. 2014;6:5–12.PubMed PubMedCentral
  28.Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf). 2008;242:7–13.CrossRef
  29.Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypetension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242:14–9.CrossRef
  30.Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.CrossRef PubMed
  31.Mastropasqua L, Agnifili L, Fasanella V, Curcio C, Ciabattoni C, Mastropasqua R, Toto L, Ciancaglini M. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013;91:e397–405.CrossRef PubMed
  32.Lorenz L, Pfeiffer N. Efficacy and safety of tafluprost 0.0015 % and timolol maleate 0.5 % fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014;15:2255–62.CrossRef PubMed
  33.Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737–47.CrossRef PubMed
  34.Pfeiffer N, Traverso CE, Lorenz K, Saarela V, Liinamaa J, Uusitalo H, Astakhov Y, Boiko E, Ropo A. A, 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015 % and timolol 0.5 % versus each of its individual preservative-free components. Adv Ther. 2014;31:1228–46.CrossRef PubMed PubMedCentral
  35.Holló G, Hommer A, López A, Ropoo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015 %/timolol 0.5 % versus concomitant use of the ingredients. J Ocula Pharmacol Ther. 2014;30:468–75.CrossRef
  36.Holló G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932–44.CrossRef PubMed PubMedCentral
  37.Locke CS. Use of a more general model for bioavailability studies. Commun Stat Theory Methods. 1990;19:3361–73.CrossRef
  38.European Medicines Agency. Guideline on the investigation of bioequivalence. London: EMEA/CHMP; 2010.
  39.Konstas AGP, Haidich A-B, Rossetti L, Webers C. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Eur J Ophthalmol. 2012;22:1–4.CrossRef PubMed
  40.Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, Floriani I. Prostaglandin analogs and timol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382–9.CrossRef PubMed
  41.Juzych MS, Zimmerman TJ. Beta blockers. In: Zimmerman TJ, Kooner KS, Sharil M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1977. p. 261–75.
  42.Uusitalo H, Niño J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, Kähönen M. Efficacy and systemic side-effects of topical 0.5 % timolol aqueous solution and 0.1 % timolol hydrogel. Acta Ophthalmol Scand. 2005;83:723–8.CrossRef PubMed
  43.Santen Oy. Taptiqom 15 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container: summary of product characteristics. 2014. http://​www.​mhra.​gov.​uk/​spc-pil/​ . Accessed 4 Sep 2015.
  
• 作者单位：Kai Kaarniranta (1)
  Kirsi Ikäheimo (1)
  Eliisa Mannermaa (1)
  Auli Ropo (2)
  
  1. Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, P.O. Box 100, FI 70029 KYS, Kuopio, Finland
  2. Santen Oy, Tampere, Finland
  
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1926

文摘

Purpose Plasma concentrations of tafluprost acid and timolol were compared after single (Day 1) and repeated (Day 8) instillations of once-daily tafluprost 0.0015 %-timolol 0.5 % preservative-free (PF) fixed-dose combination (FDC), once-daily PF tafluprost 0.0015 %, and twice-daily PF timolol 0.5 %.